VivoSeq
Other

Vasomotor Symptoms

0

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Vasomotor Symptoms is an early-stage landscape with 0 programs across 7 companies. The most active players are Bayer, Noven Therapeutics, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalN

Noven Therapeutics

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalTanabe Pharma Corporation logo

Tanabe Pharma Corporation

0 programs

PreclinicalB

BHR Pharma, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed15 · 75%
Not yet recruiting2 · 10%
Withdrawn1 · 5%
Terminated1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

20 trials

RELIEF: Real World Evidence on ELInzanEtant For the Treatment of Vasomotor Symptoms in Postmenopausal Women
Not yet recruiting·Bayer logoBayer·N/A·NCT07490431·1,500 enrolled
GOJI-VMS Pilot Study: Effects of Two Goji Berry Powder Forms on HDL Function, Vasomotor Symptoms, and Cognitive Performance
Not yet recruiting·UUniversity of California, Davis·Preclinical·NCT07660315·6 enrolled
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Completed·NNoven Therapeutics·Phase 3·NCT01101841·570 enrolled
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Completed·Bayer logoBayer·Phase 3·NCT00446199·735 enrolled
The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT00990886·148 enrolled
A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Completed·YYung Shin Pharm. Ind. Co., Ltd.·Phase 2·NCT02100540·58 enrolled
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 1·NCT02803268·24 enrolled
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
Completed·NNoven Therapeutics·Phase 3·NCT01361308·614 enrolled
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
Completed·Bayer logoBayer·Phase 3·NCT00651599·90 enrolled
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
Completed·Pfizer logoPfizer·Phase 4·NCT00195455·133 enrolled
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
Completed·Bayer logoBayer·Phase 2·NCT03596762·199 enrolled
Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Completed·LLumara Health, Inc.·Phase 3·NCT01389102·454 enrolled
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
Completed·Bayer logoBayer·Phase 1/2·NCT02865538·76 enrolled
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Completed·Pfizer logoPfizer·Phase 3·NCT00401245·500 enrolled
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
Completed·Bayer logoBayer·Phase 3·NCT00356447·249 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)